These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 16278395)

  • 1. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
    van Oers JM; Lurkin I; van Exsel AJ; Nijsen Y; van Rhijn BW; van der Aa MN; Zwarthoff EC
    Clin Cancer Res; 2005 Nov; 11(21):7743-8. PubMed ID: 16278395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
    Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
    Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
    Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC
    J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping.
    Miyake M; Sugano K; Kawashima K; Ichikawa H; Hirabayashi K; Kodama T; Fujimoto H; Kakizoe T; Kanai Y; Fujimoto K; Hirao Y
    Biochem Biophys Res Commun; 2007 Nov; 362(4):865-71. PubMed ID: 17803960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection.
    Rieger-Christ KM; Mourtzinos A; Lee PJ; Zagha RM; Cain J; Silverman M; Libertino JA; Summerhayes IC
    Cancer; 2003 Aug; 98(4):737-44. PubMed ID: 12910517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay.
    Zuiverloon TC; Tjin SS; Busstra M; Bangma CH; Boevé ER; Zwarthoff EC
    J Urol; 2011 Aug; 186(2):707-12. PubMed ID: 21683397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
    Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
    J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
    Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Amorós A; Tardón A; Carrato A; Serra C; Malats N; Real FX
    J Clin Oncol; 2006 Aug; 24(22):3664-71. PubMed ID: 16877735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
    Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
    Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
    van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
    Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of FGFR3 mutations and chromosomal alterations in bladder cancer].
    Junker K; van Oers JM; Zwarthoff EC; Kania I; Schubert J; Hartmann A
    Verh Dtsch Ges Pathol; 2006; 90():151-8. PubMed ID: 17867592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
    van Rhijn BW; Lurkin I; Radvanyi F; Kirkels WJ; van der Kwast TH; Zwarthoff EC
    Cancer Res; 2001 Feb; 61(4):1265-8. PubMed ID: 11245416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
    Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
    Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine.
    van Rhijn BW; Lurkin I; Chopin DK; Kirkels WJ; Thiery JP; van der Kwast TH; Radvanyi F; Zwarthoff EC
    Clin Cancer Res; 2003 Jan; 9(1):257-63. PubMed ID: 12538478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence of FGFR3 mutations in prostate cancer.
    Zuiverloon TC; Boormans JL; Trapman J; van Leenders GJ; Zwarthoff EC
    Prostate; 2011 May; 71(6):637-41. PubMed ID: 20957671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC).
    Roperch JP; Hennion C
    BMC Med Genet; 2020 May; 21(1):112. PubMed ID: 32448160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
    Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
    Oncogene; 2006 Apr; 25(18):2685-96. PubMed ID: 16532037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis.
    Noel N; Couteau J; Maillet G; Gobet F; D'Aloisio F; Minier C; Pfister C
    Anticancer Res; 2015 Sep; 35(9):4915-21. PubMed ID: 26254388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary study of p53 and FGFR3 gene mutations in the urine for bladder tumors].
    Noël N; Couteau J; Maillet G; Gobet F; d'Aloisio F; Minier C; Pfister C
    Prog Urol; 2013 Jan; 23(1):29-35. PubMed ID: 23287481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.